Datamonitor Healthcare: data analysis and insight, Scrip: in...
The tumor-agnostic developer’s toolkit
Recent months have seen a remarkable convergence of initiatives to foster greater European cooperation in market access. On the one hand, the EU has been promoting measures to expedite the launch of new medicines (eg adaptive pathways) and facilitate joint activity in health technology assessment. On the other hand, concerns over the pricing of some new drugs – most notably Gilead’s Sovaldi (sofosbuvir) – have prompted national governments to seek new alliances in order to help control the cost of innovative medicines. Whilst international collaboration in market access has undeniable attractions, it’s important to understand the recent changes thoroughly, especially in terms of the challenges such collaborations are likely to present in practice.
Our latest report provides an in-depth analysis into the recent key developments in the pharmaceutical market access environment and today, we are offering you a complimentary extract of this exclusive report.
This sample extract will provide you with an overview of our latest report ‘Key Trends in European Market Access’ which reviews in-depth the key developments in the pharmaceutical market access environment
Biomedtracker: follow the drug development process , Datamon...
Anticipate the biggest, most impactful expected catalysts of early 2020 with the guidance and insights from Pharma Intelligence. Building off Biomedtracker’s Early 2020 Outlook report, our live webinar will include market context for these upcoming milestones and additional insights from Datamonitor Healthcare’s Therapeutic Area Directors.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: